Innovation in prostate cancer diagnosis and treatment
Minomic is a Sydney-based biotechnology company developing new technology relating to the diagnosis and treatment of prostate cancer.
Minomic CEO Brad Walsh speaks with DibbsBarker’s Rob McInnes about how Minomic’s work has progressed since the company’s formation in 2007, and why it is so important for companies like Minomic to have a clear strategy around the protection of intellectual property rights.
For more information about Minomic, please visit their website.
If you have any further queries, please contact:
Rob McInnes | Partner
T +61 2 8233 9554
This video interview forms part of our second edition of DibbsHEALTH, DibbsBarker's e-newsletter focusing on trends and issues affecting the life sciences and healthcare sectors.
To read our first edition of DibbsHEALTH, click here.
The information in this document, broadcast or communication is provided for general guidance only. It is not legal advice, and should not be used as a substitute for consultation with professional legal or other advisors. No warranty is given to the correctness of the information contained in this document, broadcast or communication or its suitability for use by you. To the fullest extent permitted by law, no liability is accepted by DibbsBarker for any statement or opinion, or for an error or omission or for any loss or damage suffered as a result of reliance on or use by any person of any material in the document, broadcast or communication.
This webcast is copyright. Apart from any use as permitted under the Copyright Act 1968, it may only be reproduced for internal business purposes, and may not otherwise be copied, adapted, amended, published, communicated or otherwise made available to third parties, in whole or in part, in any form or by any means, without the prior written consent of DibbsBarker.